Overview
ANGO market data
Price History
ANGO price chart
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$0.88 Diluted earnings per share over the trailing twelve months.
- Beta
- 0.30 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- — Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $8.36 – $15.20 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · source Twelve Data /statistics · market cap $561.3 · P/B 2.64 · P/S 1.75.
Company news
HC Wainwright & Co. Maintains Buy on AngioDynamics, Raises Price Target to $19Benzinga · Jul 15, 2026, 5:07 PM
Canaccord Genuity Maintains Buy on AngioDynamics, Raises Price Target to $20Benzinga · Jul 15, 2026, 2:40 PM
Full Transcript: AngioDynamics Q4 2026 Earnings CallBenzinga · Jul 14, 2026, 1:02 PM
8-K filing — ANGIODYNAMICS INC (ANGO)SEC EDGAR · Jul 14, 2026, 11:30 AM
Earnings Scheduled For July 14, 2026Benzinga · Jul 14, 2026, 11:11 AM
AngioDynamics Sees FY2027 Adj EPS $(0.29)-$(0.24) vs $(0.16) Est; Sees Sales $336.000M-$341.000M vs $329.600M EstBenzinga · Jul 14, 2026, 10:03 AM
AngioDynamics Q4 Adj. EPS $(0.07) Beats $(0.09) Estimate, Sales $86.607M Beat $80.400M EstimateBenzinga · Jul 14, 2026, 10:02 AM
AngioDynamics Says FDA Approves IDE Application To Initiate RELIEF Study Evaluating NanoKnife IRE Platform As Minimally Invasive Treatment Option For Men With Benign Prostatic HyperplasiaBenzinga · Jun 17, 2026, 12:45 PM
AngioDynamics Announces 2-Yr Results From PRESERVE Pivotal Trial Demonstrating Durable Oncologic Control And Sustained Safety Profile For NanoKnife System In Focal Ablation Of Intermediate-Risk Prostate CancerBenzinga · May 13, 2026, 1:06 PM